Advisory Intelligence: ‘Deals and data’ are heartbeat of biotech

Jun 08, 2021
Jeff Larocque, senior biotech analyst with Nasdaq IR Intelligence, discusses the outlook for the biotech sector

Sponsored content

For companies in the biotech sector, 2021 is off to a fast start as capital-raising among new issuers crossed $6.1 bn as of June 1. The US market has welcomed 45 new biotech listings in the first five months of the year, a staggering increase of 200 percent on the same period in 2020.

Following months of relative outperformance last year, however, the biotech sector may face some uncertainty in the coming months, says Jeff Larocque, senior biotech analyst at Nasdaq IR Intelligence.

The Nasdaq Biotech Index reached an all-time high in early February 2021, following the outperformance of biotech, gene-editing and therapeutics companies during 2020. But February’s market correction coupled with uncertainty around the actions of the Federal Trade Commission (FTC) and a backlog at the Food and Drug Administration (FDA) could cause a slowdown in the coming months.

‘Biotech was a quick sell in February as investors were concerned that some of these biotech firms would be crunched and may struggle to continue to grow,’ Larocque says. ‘The heartbeat of biotech is deals and data. Those two things fuel the industry. If you see that start to scale back, it could be a reason for investors to take their foot off the pedal.’

In March 2021 the FTC announced the formation of a cross-border working group – along with Canada’s Competition Bureau, the European Commission’s Directorate-General for Competition, the UK’s Competition and Markets Authority, the US Department of Justice Antitrust Division and the offices of state attorneys general – to update their approach to analyzing pharmaceutical mergers.

It’s broadly anticipated that during the Biden administration, the FTC will take a tougher stance on pharmaceutical mergers, which will have a knock-on effect on investor enthusiasm for biotech companies. Larocque points to the FTC’s recent efforts to block Illumina’s acquisition of Grail, on the grounds that it could reduce competition in the market, as a potential sign of things to come.

‘The FTC likes to create a competitive landscape by keeping a level playing field,’ Larocque explains. ‘We know there’s going to be more scrutiny on deals in the future, and that’s going to keep some of the event-driven investors on the sidelines.’

Despite the concern around how active the FTC may be in the future, Larocque says February’s market correction could play into the hands of some large pharma companies. ‘Since mid-February, prices have been under pressure and this might be the window for large-cap pharma firms to look for value – even if they take more of a critical approach to the names they pick up than they would have done before.’

Elsewhere in the federal government, the backlog of drug approvals by the FDA – caused by the inability of the authority to access facilities during the last year – could also cause some conservatism from investors.

In early May the FDA announced that it is prioritizing mission-critical and domestic inspections for the next few months, before returning to standard inspections later this year. If all goes to plan, it expects to have cleared 26 percent of its backlog of product inspections by October.

But taking a broader view of the last 18 months is instructive, Larocque says: 2020 was ‘an incredible year’ for the biotech sector, with ‘big investors’ taking an interest in the sector and participating in capital-raises. Coupled with the enthusiasm of retail investors around the development of the mRNA technology – which has been so influential in providing the technology for the Moderna and Pfizer Covid-19 vaccines – there’s plenty for biotech executives to still feel optimistic about.

Sign up to get stories direct to your inbox
logo-black logo-black
Loading